Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | USP7 | Q93009 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13085918 | 0.88 | HRH3 (0.74) | HRH3HDAC1HDAC6MGLLUSP7 | |
| SCHEMBL13085756 | 0.88 | HRH3 (0.74) | HRH3HDAC1HDAC6MGLLUSP7 | |
| SCHEMBL2879302 | 0.87 | HRH3 (0.56) | HRH3MGLLCYP11B2 | |
| SCHEMBL2884617 | 0.85 | HRH3 (1.00) | HRH3HDAC1HDAC6MGLL | |
| SCHEMBL2883533 | 0.85 | HRH3 (1.00) | HRH3HDAC1HDAC6MGLL | |
| SCHEMBL2883495 | 0.85 | HRH3 (1.00) | HRH3HDAC1HDAC6MGLLUSP7 | |
| SCHEMBL2884190 | 0.82 | HRH3 (0.84) | HRH3HDAC1HDAC6MGLLUSP7 | |
| SCHEMBL2884990 | 0.82 | HRH3 (0.91) | HRH3HDAC1HDAC6MGLL | |
| SCHEMBL2885133 | 0.81 | HRH3 (0.89) | HRH3HDAC1HDAC6MGLL | |
| SCHEMBL2884787 | 0.81 | HRH3 (0.75) | HRH3HDAC1HDAC6MGLLUSP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1994022-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007108936-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | HNMT, HRH4, HRH3 | HRH3 3/4885HDAC1 701/4885HDAC6 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.